Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-10-28

Clinical Trial Update: A Study Of BRL49653C For The Treatment Of Type 2 Diabetes [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating BRL49653C for type 2 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BRL49653C

Snippet

Sponsor: GlaxoSmithKline | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED